Cormica Develops Dual-Detection HPLC Method for Potent API Classification

As the pharmaceutical industry continues to handle increasingly potent active pharmaceutical ingredients (APIs), the need for robust, validated analytical methods to support occupational exposure banding (OEB) and containment strategy decisions has never been greater. Cormica, a specialist in pharmaceutical analytical and EHS services, has developed a dual-detection HPLC methodology using both UV and fluorescence (FLD) detection to support surrogate molecule programs targeting compounds across multiple OEL bands.

Surrogate molecules are non-hazardous compounds used to simulate the behaviour of potent APIs during cleaning validation, containment qualification, and operator exposure assessments. Selecting the right surrogate and being able to detect it at trace levels is critical to ensuring that containment systems perform as intended before a facility handles a genuinely hazardous compound.

Cormica's analytical approach centres on a five-minute HPLC run time, enabling high-throughput sample processing without sacrificing sensitivity. The method employs UV detection across a defined linear range suited to higher-concentration samples, while fluorescence detection extends sensitivity to lower limits, achieving limits of detection (LOD) and quantification (LOQ) appropriate for trace-level surrogate recovery studies in containment qualification scenarios.

The dual-detector configuration is particularly valuable when surrogate concentrations span several orders of magnitude across different sample types, such as wipe samples from equipment surfaces versus air monitoring filters. UV detection handles the upper concentration range with precision, while FLD provides the sensitivity required at the lower end, ensuring a single method can serve multiple sampling matrices without requiring separate method development for each application.

From a regulatory standpoint, surrogate molecule programs are increasingly referenced within ISPE's OEB framework guidance and align with EMA expectations for potent compound handling in manufacturing environments. Demonstrating that a containment system can achieve the required performance level, typically expressed as an airborne exposure limit or surface recovery target, before introducing a potent API is considered best practice and, in many jurisdictions, a regulatory expectation.

The five-minute analytical cycle time also has direct operational implications. Faster turnaround on surrogate recovery data means containment qualification campaigns can be completed more efficiently, reducing the time between facility commissioning and first-in-human or commercial manufacturing campaigns. For contract development and manufacturing organisations (CDMOs) operating across multiple OEB bands, this throughput advantage translates into meaningful schedule and cost benefits.

Cormica's method development work reflects a broader industry trend toward fit-for-purpose analytical tools that bridge the gap between EHS requirements and manufacturing readiness. By combining sensitivity, speed, and dual-detection flexibility, the methodology supports a more integrated approach to potent compound risk management, from early-stage OEB assignment through to full-scale containment qualification and routine monitoring.

As pipelines continue to skew toward higher-potency compounds, analytical capabilities of this kind are expected to become a standard component of pharmaceutical EHS and quality programmes worldwide.